Abstract
Background: Soluble interleukin 4 receptors (sIL–4R) are present in biological fluids. In contrast to mice, in man no distinct mRNA coding for sIL–4R has been described, suggesting that human sIL–4R is exclusively produced by proteolytic cleavage of the cell surface receptor. It is not known whether human sIL–4R is actively produced during an immune response. Methods: Human purified T cells, CD4+, CD8+, CD45RA+ and CD45R0+ T cell subpopulations were activated in vitro. sIL–4R was determined in the supernatants, cell surface IL–4R was measured by flow cytometry and RT–PCR. Results: Recombinant sIL–4R inhibited IL–4–mediated proliferation and IL–5 upregulation by T cells. sIL–4R could be detected at low levels in supernatants of nonactivated T cells, but at high levels following TCR engagement. This response was paralleled by enhanced transcription and de novo synthesis of the human cell surface IL–4R. Both, activated naive CD45RA+ and memory CD45R0+ T cells, produced sIL–4R with long–lasting kinetics. IL–4 increased sIL–4R production by activated CD45RA+, but there was less of an increase by CD45R0+ T cells. In addition, interferon–γ enhanced sIL–4R production. Cycloheximide and dexamethasone inhibited sIL–4R production by activated T cells, but did not abolish constitutive release of sIL–4R. Phosphoramidon and 1,10–phenanthroline dose–dependently inhibited shedding of the IL–4R, even in nonactivated T cells. Conclusion: The production of human sIL–4R by T cells is regulated by TCR stimuli, IL–4 and IFN–γ and needs the activity of metalloproteinases. Thus, sIL–4R should be regarded as inducible and due to its IL–4–antagonizing activity an immunoregulatory molecule.
References
1.
Idzerda RL, March CJ, Mosley B, Lyman SD, Bos TV, Gimpel SD, Din WS, Grabstein KH, Widmer MB, Park LS, Cosman D, Beckmann MP: Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily. J Exp Med 1990;171:861– 873.
2.
Russell SM, Keegan AD, Harada N, Nakamura Y, Noguchi M, Leland P, Friedmann MC, Miyajima A, Puri RK, Paul WE, et al: Interleukin–2 receptor gamma chain: A functional component of the interleukin–4 receptor. Science 1993;262:1880–1883.
3.
Hilton DJ, Zhang JG, Metcalf D, Alexander WS, Nicola NA, Willson TA: Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc Natl Acad Sci USA 1996;93:497–501.
4.
Fernandez Botran R, Ritetta ES: A soluble, high–affinity, interleukin–4–binding protein is present in the biological fluids of mice. Proc Natl Acad Sci USA 1990;87:4202–4206.
5.
Novick D, Engelmann H, Wallach D, Rubinstein M: Soluble cytokine receptors are present in normal human urine. J Exp Med 1989;170: 1409–1414.
6.
Heaney ML, Golde DW: Soluble cytokine receptors. Blood 1996;87:847–857.
7.
Mosley B, Beckmann MP, March CJ, Idzerda RL, Gimpel SD, VandenBos T, Friend D, Alpert A, Anderson D, Jackson J, et al: The murine interleukin–4 receptor: Molecular cloning and characterization of secreted and membrane bound forms. Cell 1989;59:335– 348.
8.
Garrone P, Djossou O, Galizzi JP, Banchereau J: A recombinant extracellular domain of the human interleukin 4 receptor inhibits the biological effects of interleukin 4 on T and B lymphocytes. Eur J Immunol 1991;21:1365–1369.
9.
Enssle K, Enders B, Kurrle R, Lauffer L, Schorlemmer HU, Dickneite G, Kanzy EJ, Seiler FR: Biology of natural and recombinant soluble interleukin–4 receptor. Behring Inst Mitt 1995;96:103–117.
10.
Gessner A, Schroppel K, Will A, Enssle KH, Lauffer L, Rollinghoff M: Recombinant soluble interleukin–4 (IL–4) receptor acts as an antagonist of IL–4 in murine cutaneous leishmaniasis. Infect Immun 1994;62:4112–4117.
11.
Renz H, Bradley K, Enssle K, Loader JE, Larsen GL, Gelfand EW: Prevention of the development of immediate hypersensitivity and airway hyperresponsiveness following in vivo treatment with soluble IL–4 receptor. Int Arch Allergy Immunol 1996;109:167–176.
12.
Fernandez Botran R, Vitetta ES: Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins. J Exp Med 1991; 174:673–681.
13.
Sato TA, Widmer MB, Finkelman FD, Madani H, Jacobs CA, Grabstein KH, Maliszewski CR: Recombinant soluble murine IL–4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 1993;150:2717–2723.
14.
Chilton PM, Fernandez Botran R: Production of soluble IL–4 receptors by murine spleen cells is regulated by T cell activation and IL–4. J Immunol 1993;151:5907–5917.
15.
Renz H, Domenico J, Gelfand EW: IL–4–dependent up–regulation of IL–4 receptor expression in murine T and B cells. J Immunol 1991; 146:3049–3055.
16.
Blum H, Wolf M, Enssle K, Rollinghoff M, Gessner A: Two distinct stimulus–dependent pathways lead to production of soluble murine interleukin–4 receptor. J Immunol 1996;157: 1846–1853.
17.
Fernandez Botran R, Wynn TA, Hieny S, Caspar P, Chilton PM, Sher A: Linded in vivo expression of soluble interleukin–4 receptor and interleukin–4 in murine schistosomiasis. Eur J Immunol 1995;25:649–656.
18.
Foxwell BMJ, Woerly G, Ryffel B: Identification of interleukin 4 receptor–associated proteins and expression of both high– and low–affinity binding on human lymphoid cells. Eur J Immunol 1989;19:1637–1641.
19.
Byron KA, Varigos GA, Wootton AM: Recombinant interferon–gamma inhibits the expression of IL–4 receptors on human lymphocytes. Clin Exp Immunol 1991;85:307–311.
20.
Jung T, Schauer U, Heusser C, Neumann C, Rieger C: Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993; 159:197–207.
21.
Sager N, Feldmann A, Schilling G, Kreitsch P, Neumann C: House dust mite–specific T cells in the skin of subjects with atopic dermatitis: Frequency and lymphokine profile in the allergen patch test. J Allergy Clin Immunol 1992; 89:801–810.
22.
Schauer U, Schmitt M, Müller S, Enssle K, Kurrle R, Sundermann U, Bender A, Wahn U, Rieger CHL: Soluble interleukin–4 receptor in atopic children. Int Arch Allergy Immunol 1995;108:175:182.
23.
Beverley PC: Functional analysis of human T cell subsets defined by CD45 isoform expression. Semin Immunol 1992;4:35–41.
24.
Jung T, Wijdenes, J, Neumann C, de Vries JE, Yssel H: Interleukin–13 is produced by activated human CD45RA+ and CD45R0+ T cells. Modulation by interleukin–4 and interleukin–12. Eur J Immunol 1996;26:571–577.
25.
Demeure CE, Yang LP, Byun DG, Ishihara H, Vezzio N, Delespesse G: Human naive CD4 T cells produce interleukin–4 at priming and aquire a Th2 phenotype upon repetitive stimulations in neutral conditions. Eur J Immunol 1995;25:2722–2725.
26.
Fernandez Botran R, Chilton PM, Ma Y, Windsor JL, Street NE: Control of the production of soluble interleukin–4 receptors: Implications in immunoregulation. J Leukoc Biol 1996;59: 499–504.
27.
Fernandez Botran R, Chilton PM, Ma Y, Windsor JL, Street NE: The production of soluble interleukin 4 receptors is preferentially regulated by the murine Th2 cell subset. Cytokine 1997;9:166–177.
28.
Renz H, Jujo K, Bradley KL, Domenico J, Gelfand EW, Leung DY: Enhanced IL–4 production and IL–4 receptor expression in atopic dermatitis and their modulation by interferon–gamma. J Invest Dermatol 1992;99:403–408.
29.
Crowe PD, Walter BN, Mohler KM, Otten Evans C, Black RA, Ware CF: A metalloprotease inhibitor blocks shedding of the 80–kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 1995;181:1205–1210.
30.
Müllberg J, Durie FH, Otten–Evans C, Alderson MR, Rose–John S, Cosman D, Black RA, Mohler KM: A metalloprotease inhibitor blocks shedding of the IL–6 receptor and the p60 TNF receptor. J Immunol 1995;155: 5198–5205.
31.
Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL: T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379–4389.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
